10 terminated. 10 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Terminated 10 |
| Phase 1 | 2 | Terminated 2 |
| Phase 3 | 1 | Terminated 1 |
Follow Soliris: new trials by email Literature Review of Soliris trials Research Report on Soliris
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor Therapy Eculizumab, Ravulizumab, BCX9930 - Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 2 | Terminated | BioCryst Pharmaceuticals | 12 | 2021-12-06 | 2025-03-07 |
| Complement Regulation to Undo Systemic Harm in Preeclampsia Eculizumab - Preeclampsia, Severe Preeclampsia | Phase 2 | Terminated | Cedars-Sinai Medical Center | 2 | 2021-09-13 | 2023-11-29 |
| A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder Eculizumab - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 5 | 2020-01-14 | 2024-09-25 |
| Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation Eculizumab, Immunoglobulin, Plasmapheresis - Antibody-mediated Rejection, Humoral Rejection | Phase 2 | Terminated | Brigham and Women's Hospital | 11 | 2013-11-01 | 2017-09-21 |
| Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation Eculizumab, Normal Saline - Delayed Graft Function, Kidney Transplantation | Phase 2 | Terminated | Heeger, Peter, M.D. | 21 | 2013-08-01 | 2018-02-27 |
| A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant Eculizumab, Placebo - Delayed Function of Renal Transplant | Phase 2 | Terminated | Schroppel, Bernd, M.D. | 8 | 2011-12-01 | 2019-05-06 |
| Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization Eculizumab - Antibody Mediated Rejection | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 102 | 2011-11-02 | 2017-10-03 |
| Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation Eculizumab - Kidney Transplant | Phase 1 / Phase 2 | Terminated | Mayo Clinic | 6 | 2010-05-01 | 2015-07-20 |
| Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant Eculizumab - Kidney Transplant | Phase 1 / Phase 2 | Terminated | Mayo Clinic | 2 | 2010-03-01 | 2018-01-31 |
| Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis eculizumab, Placebo - Myasthenia Gravis | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 14 | 2008-10-01 | 2019-09-24 |
Delayed Graft Function (2) · Demyelinating Diseases (1) · HELLP Syndrome (1) · Hemoglobinuria, Paroxysmal (1) · Myasthenia Gravis (1) · Myelitis, Transverse (1) · Neuromyelitis Optica (1) · Optic Neuritis (1) · Pre-Eclampsia (1) · Recurrence (1) · Rejection, Psychology (1)
Alexion Pharmaceuticals, Inc. (3) · Mayo Clinic (2) · BioCryst Pharmaceuticals (1) · Brigham and Women's Hospital (1) · Cedars-Sinai Medical Center (1) · Heeger, Peter, M.D. (1) · Schroppel, Bernd, M.D. (1)
United States (9) · Italy (3) · Spain (3) · United Kingdom (3) · Canada (2) · France (2) · Germany (2) · Australia (1) · Hungary (1) · Japan (1) · Netherlands (1) · Norway (1) · South Korea (1) · Sweden (1)
Anil K Chandraker, MD (1) · Austin G Kulasekararaj, MBBS, MD (1) · Bernd Schroppel, MD (1) · Mark D Stegall (1) · Mark Stegall, MD (1) · Masayo Ogawa, MD (1) · Peter S Heeger, MD (1) · Richard Burwick, MD, MPH (1)
2019 (1), UL1TR000135 (1)